Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco, California

BMC Infectious Diseases

Kimberly Page⁶  Michael P Busch⁷  Steve Deeks¹  Alex Kral³  Jennifer Evans²  Paula Lum¹  Jeff Martin⁸  Brian R Edlin⁸  Eric Delwart⁵  Judith A Hahn⁴  Paulo Telles Dias² 

[1] Department of Medicine, Positive Health Program, San Francisco General Hospital, Box 0874, SFGH Bldg 100 335; University of California San Francisco, San Francisco, CA. 94143 - 0811, USA;Department of Epidemiology and Biostatistics, Division of Preventive Medicine and Public Health, Box 1224, 50 Beale Street 1200 University of California San Francisco, San Francisco, CA USA;Research Triangle Institute (RTI), San Francisco, CA USA;Department of Medicine, Division of Infectious Disease, San Francisco General Hospital, Box 0811, SFGH Bldg 100 335; University of California San Francisco, San Francisco, CA. 94143 - 0811, USA;Blood Systems Research Institute, 270 Masonic Avenue, San Francisco, CA 94118, USA;Department of Epidemiology and Biostatistics, Division of Clinical Epidemiology, Box 0560, 185 Berry Street 5700, University of California San Francisco, San Francisco, CA. 94143 - 0560, USA;Department of Laboratory Medicine, Box 0134, University of California San Francisco San Francisco, CA. 94143 - 0134 USA;Department of Medicine, SUNY Downstate College of Medicine, 450 Clarkson Avenue, Box 1240, Brooklyn, NY 11203. USA

关键词: African-American;    birth cohort;    HIV;    injection drug use;    GT;    HCV;    hepatitis C virus;   

Others  :  1175641
DOI  :  10.1186/1471-2334-11-208

 received in 2011-01-27, accepted in 2011-08-02,  发布年份 2011

【 摘 要 】

Background

Hepatitis C virus (HCV) genotype (GT) has become an important measure in the diagnosis and monitoring of HCV infection treatment. In the United States (U.S.) HCV GT 1 is reported as the most common infecting GT among chronically infected patients. In Europe, however, recent studies have suggested that the epidemiology of HCV GTs is changing.

Methods

We assessed HCV GT distribution in 460 patients from three HCV-infected high risk populations in San Francisco, and examined patterns by birth cohort to assess temporal trends. Multiple logistic regression was used to assess factors independently associated with GT 1 infection compared to other GTs (2, 3, and 4).

Results

Overall, GT 1 was predominant (72.4%), however younger injection drug users (IDU) had a lower proportion of GT 1 infections (54.7%) compared to older IDU and HIV-infected patients (80.5% and 76.6%, respectively). Analysis by birth cohort showed increasing proportions of non-GT 1 infections associated with year of birth: birth before 1970 was independently associated with higher adjusted odds of GT 1: AOR 2.03 (95% CI: 1.23, 3.34). African-Americans as compared to whites also had higher adjusted odds of GT 1 infection (AOR: 3.37; 95% CI: 1.89, 5.99).

Conclusions

Although, HCV GT 1 remains the most prevalent GT, especially among older groups, changes in GT distribution could have significant implications for how HCV might be controlled on a population level and treated on an individual level.

【 授权许可】

   
2011 Dias et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, Halfon P, Inchauspe G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin IT, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A: Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005, 42(4):962-973.
• [2]Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347(13):975-982.
• [3]Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358(9286):958-965.
• [4]Muir AJ, Bornstein JD, Killenberg PG: Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004, 350(22):2265-2271.
• [5]McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group [see comments]. N Engl J Med 1998, 339(21):1485-1492.
• [6]Tobler LH, Bahrami SH, Kaidarova Z, Pitina L, Winkelman VK, Vanderpool SK, Guiltinan AM, Cooper S, Busch MP, Murphy EL: A case-control study of factors associated with resolution of hepatitis C viremia in former blood donors (CME). Transfusion 50(7):1513-1523.
• [7]Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, galai N, Nolt K, Nelson KE, Strathdee SA, Johnson L, Laeyendecker O, Boitnott J, Wilson LE, Vlahov D: The natural history of hepatitis C virus infection. Journal of the American Medical Association 2000, 284(4):450-456.
• [8]Schito ML, D'Souza MP, Owen SM, Busch MP: Challenges for rapid molecular HIV diagnostics. J Infect Dis 201(Suppl 1):S1-6.
• [9]Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP, Sobesky R, Martinot-Peignoux M, Maylin S, Nicolas-Chanoine MH, Paradis V, Vidaud M, Valla D, Bedossa P, Marcellin P: Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008, 134(2):416-423.
• [10]Yoo TW, Donfield S, Lail A, Lynn HS, Daar ES: Effect of hepatitis C virus (HCV) genotype on HCV and HIV-1 disease. J Infect Dis 2005, 191(1):4-10.
• [11]Farci P, Purcell RH: Clinical significance of hepatitis C virus genotypes and quasispecies. Semin Liver Dis 2000, 20(1):103-126.
• [12]Hepburn MJ, Hepburn LM, Cantu NS, Lapeer MG, Lawitz EJ: Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med 2004, 117(3):163-168.
• [13]Kinzie JL, Naylor PH, Nathani MG, Peleman RR, Ehrinpreis MN, Lybik M, Turner JR, Janisse JJ, Massanari M, Mutchnick MG: African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians. J Viral Hepat 2001, 8(4):264-269.
• [14]Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461(7262):399-401.
• [15]Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M: Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461(7265):798-801.
• [16]Strickland GT, El-Kamary SS, Klenerman P, Nicosia A: Hepatitis C vaccine: supply and demand. Lancet Infect Dis 2008, 8(6):379-386.
• [17]Alter MJ: Hepatitis C virus infection in the United States. J Hepatol 1999, 31(Suppl 1):88-91.
• [18]Blatt LM, Mutchnick MG, Tong MJ, Klion FM, Lebovics E, Freilich B, Bach N, Smith C, Herrera J, Tobias H, Conrad A, Schmid P, McHutchison JG: Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepat 2000, 7(3):196-202.
• [19]Nainan OV, Alter MJ, Kruszon-Moran D, Gao FX, Xia G, McQuillan G, Margolis HS: Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology 2006, 131(2):478-484.
• [20]Payan C, Roudot-Thoraval F, Marcellin P, Bled N, Duverlie G, Fouchard-Hubert I, Trimoulet P, Couzigou P, Cointe D, Chaput C, Henquell C, Abergel A, Pawlotsky JM, Hezode C, Coude M, Blanchi A, Alain S, Loustaud-Ratti V, Chevallier P, Trepo C, Gerolami V, Portal I, Halfon P, Bourliere M, Bogard M, Plouvier E, Laffont C, Agius G, Silvain C, Brodard V, et al.: Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. J Viral Hepat 2005, 12(4):405-413.
• [21]Chlabicz S, Flisiak R, Kowalczuk O, Grzeszczuk A, Pytel-Krolczuk B, Prokopowicz D, Chyczewski L: Changing HCV genotypes distribution in Poland--relation to source and time of infection. J Clin Virol 2008, 42(2):156-159.
• [22]Bourliere M, Barberin JM, Rotily M, Guagliardo V, Portal I, Lecomte L, Benali S, Boustiere C, Perrier H, Jullien M, Lambot G, Loyer R, LeBars O, Daniel R, Khiri H, Halfon P: Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users. J Viral Hepat 2002, 9(1):62-70.
• [23]Katsoulidou A, Sypsa V, Tassopoulos NC, Boletis J, Karafoulidou A, Ketikoglou I, Tsantoulas D, Vafiadi I, Hatzis G, Skoutelis A, Akriviadis E, Vasiliadis T, Kitis G, Magiorkinis G, Hatzakis A: Molecular epidemiology of hepatitis C virus (HCV) in Greece: temporal trends in HCV genotype-specific incidence and molecular characterization of genotype 4 isolates. J Viral Hepat 2006, 13(1):19-27.
• [24]Schroter M, Zollner B, Schafer P, Reimer A, Muller M, Laufs R, Feucht HH: Epidemiological dynamics of hepatitis C virus among 747 German individuals: new subtypes on the advance. J Clin Microbiol 2002, 40(5):1866-1868.
• [25]Lorvick J, Kral AH, Seal K, Gee L, Edlin BR: Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif. Am J Public Health 2001, 91(1):46-47.
• [26]Page K, Hahn JA, Evans J, Shiboski S, Lum P, Delwart E, Tobler L, Andrews W, Avanesyan L, Cooper S, Busch MP: Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis 2009, 200(8):1216-1226.
• [27]Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Page-Shafer K, Hsue P, Emu B, Krone M, Lampiris H, Douek D, Martin JN, Deeks SG: Relationship between T Cell Activation and CD4(+) T Cell Count in HIV-Seropositive Individuals with Undetectable Plasma HIV RNA Levels in the Absence of Therapy. J Infect Dis 2008, 197(1):126-133.
• [28]Gish RG, Qian K, Brooks L, Leung J, Xu Y, Pike I, Lau JY: Characterization of anti-hepatitis C virus-positive sera not genotyped by restriction fragment length polymorphism or serology. J Gastroenterol Hepatol 1999, 14(4):339-344.
• [29]Simmonds P, Mellor J, Craxi A, Sanchez-Tapias JM, Alberti A, Prieto J, Colombo M, Rumi MG, Lo Iacano O, Ampurdanes-Mingall S, Forns-Bernhardt X, Chemello L, Civeira MP, Frost C, Dusheiko G: Epidemiological, clinical and therapeutic associations of hepatitis C types in western European patients. J Hepatol 1996, 24(5):517-524.
• [30]Dal Molin G, Ansaldi F, Biagi C, D'Agaro P, Comar M, Croce L, Tiribelli C, Campello C: Changing molecular epidemiology of hepatitis C virus infection in Northeast Italy. J Med Virol 2002, 68(3):352-356.
• [31]Mathei C, Wollants E, Verbeeck J, Van Ranst M, Robaeys G, Van Damme P, Buntinx F: Molecular epidemiology of hepatitis C among drug users in Flanders, Belgium: association of genotype with clinical parameters and with sex- and drug-related risk behaviours. Eur J Clin Microbiol Infect Dis 2005, 24(8):514-522.
• [32]van Asten L, Verhaest I, Lamzira S, Hernandez-Aguado I, Zangerle R, Boufassa F, Rezza G, Broers B, Robertson JR, Brettle RP, McMenamin J, Prins M, Cochrane A, Simmonds P, Coutinho RA, Bruisten S: Spread of hepatitis C virus among European injection drug users infected with HIV: a phylogenetic analysis. J Infect Dis 2004, 189(2):292-302.
• [33]Armstrong GL: Injection drug users in the United States, 1979-2002: an aging population. Arch Intern Med 2007, 167(2):166-173.
• [34]Bluthenthal RN, Do DP, Finch B, Martinez A, Edlin BR, Kral AH: Community characteristics associated with HIV risk among injection drug users in the San Francisco Bay Area: a multilevel analysis. J Urban Health 2007, 84(5):653-666.
• [35]Johnson RA, Gerstein DR, Pach A, Cerbone FG, Brown J: HIV risk behaviors in African-American drug injector networks: implications of injection-partner mixing and partnership characteristics. Addiction 2002, 97(8):1011-1024.
• [36]Friedman SR, Lieb S, Tempalski B, Cooper H, Keem M, Friedman R, Flom PL: HIV among injection drug users in large US metropolitan areas, 1998. J Urban Health 2005, 82(3):434-445.
• [37]Cooper HL, Bossak BH, Tempalski B, Friedman SR, Des Jarlais DC: Temporal trends in spatial access to pharmacies that sell over-the-counter syringes in New York City health districts: relationship to local racial/ethnic composition and need. J Urban Health 2009, 86(6):929-945.
• [38]Heinzerling KG, Kral AH, Flynn NM, Anderson RL, Scott A, Gilbert ML, Asch SM, Bluthenthal RN: Human immunodeficiency virus and hepatitis C virus testing services at syringe exchange programs: availability and outcomes. J Subst Abuse Treat 2007, 32(4):423-429.
• [39]Stopka TJ, Garfein RS, Ross A, Truax SR: Increasing syringe access and HIV prevention in California: findings from a survey of local health jurisdiction key personnel. J Urban Health 2007, 84(1):116-125.
• [40]Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M: Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009.
• [41]Serra MA, Rodriguez F, del Olmo JA, Escudero A, Rodrigo JM: Influence of age and date of infection on distribution of hepatitis C virus genotypes and fibrosis stage. J Viral Hepat 2003, 10(3):183-188.
• [42]Germer JJ, Mandrekar JN, Bendel JL, Mitchell PS, Yao JD: Hepatitis C Virus Genotypes in Clinical Specimens Tested at a National Reference Testing Laboratory in the United States. J Clin Microbiol 2011.
• [43]Nadarajah R, Khan GY, Miller SA, Brooks GF: Evaluation of a new-generation line-probe assay that detects 5' untranslated and core regions to genotype and subtype hepatitis C virus. Am J Clin Pathol 2007, 128(2):300-304.
• [44]Herring BL, Page-Shafer K, Tobler LH, Delwart EL: Frequent hepatitis C virus superinfection in injection drug users. J Infect Dis 2004, 190(8):1396-1403.
• [45]Schroter M, Feucht HH, Zollner B, Schafer P, Laufs R: Multiple infections with different HCV genotypes: prevalence and clinical impact. J Clin Virol 2003, 27(2):200-204.